Drug Candidates for Gastric Cancer

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (23 February 2023) | Viewed by 2266

Special Issue Editors


E-Mail Website
Guest Editor
AI Convergence Center for Medical Science, Department of Genome Medicine and Science, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Korea
Interests: gastric cancer; drug discovery process; artificial intelligence; drug repurposing; biomarker discovery

E-Mail Website
Guest Editor
Korea Research Institute of Bioscience and Biotechnology, Korean Bioinformation Center (KOBIC), Daejeon 305-806, Korea
Interests: computational chemistry; drug discovery; molecular dynamics; molecular docking; structure–activity relationship (SAR)

Special Issue Information

Dear Colleagues,

Our understanding of the biology of gastric cancer (GC) has substantially improved over the last decade, leading to advances in targeted therapies and novel therapeutic approaches.

Recent breakthroughs in potential therapeutic candidates for GC, as well as innovations in neoadjuvant and adjuvant chemotherapy, immunotherapy, and radiation treatment for GC, will be discussed in this Special Issue. This Special Issue will also discuss the roles of emerging therapeutics in both clinical and investigational fields, such as rational and structure-based drug design, which have the potential to improve the clinical outcome of these illnesses. Reviews and research papers are both welcome.

Regarding GC, potential topics include, but are not limited to, the following: experimental therapeutics, drug candidates, drug repurposing, drug target discovery, drug screening, artificial intelligence in drug discovery, computational methods for drug repurposing and drug design, molecular dynamics, and molecular docking.

Dr. Seungyoon Nam
Dr. Jinhyuk Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • drug candidates
  • drug discovery
  • drug repurposing
  • drug screening
  • artificial intelligence

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 286 KiB  
Review
Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma
by Emer Lynch, Austin G. Duffy and Ronan J. Kelly
Pharmaceuticals 2023, 16(1), 102; https://doi.org/10.3390/ph16010102 - 10 Jan 2023
Viewed by 1955
Abstract
In the West, recent decades have demonstrated an epidemiological trend towards esophago-gastric adenocarcinomas (EGAC), with considerable associated mortality. Historically, chemotherapy has represented the sole systemic treatment option in the advanced EGAC setting, in addition to complementing the role of surgery and radiotherapy in [...] Read more.
In the West, recent decades have demonstrated an epidemiological trend towards esophago-gastric adenocarcinomas (EGAC), with considerable associated mortality. Historically, chemotherapy has represented the sole systemic treatment option in the advanced EGAC setting, in addition to complementing the role of surgery and radiotherapy in the case of localized disease. Immune checkpoint inhibitors (ICIs) represent a novel systemic therapeutic choice and have revolutionized the management of other malignancies, including melanoma and renal cell carcinomas. This article considers the rationale for ICIs in EGAC, reviews the evidence supporting their role in the current standard of care in EGAC, and briefly considers ongoing trials and future directions for the ICI class in EGAC. Full article
(This article belongs to the Special Issue Drug Candidates for Gastric Cancer)
Back to TopTop